ReviewLife (Basel, Switzerland)2026
Hypertension and Valvular Heart Disease: An Overview of a Complex and Clinically Meaningful Relationship.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular Diseases: From Basic Research to Clinical Application-3rd Edition.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overlooked relationship between hypertension (HTN) and valvular heart disease (VHD) has been brought to wider attention by large-scale population studies and the latest guidelines. Approximately 45% of patients with VHD have been diagnosed with HTN. This association increases with age, but cannot be explained solely by the rising prevalence of both conditions. HTN promotes the onset or worsening of VHD by mechanically stressing the valves and by modified blood flow dynamics through increased filling pressures and afterload. It has been shown that a 20 mmHg rise in BP triples the risk of aortic valvular disease and mitral regurgitation. This review will address the impact of HTN on the occurrence and progression of valvular lesions, its effect on the prognosis of patients with VHD, and the available data on blood pressure management. As long as relatively well-documented data on aortic valve disease are available, studies are still needed to clarify target blood pressure values under therapy and the most appropriate drug classes for mitral regurgitation, especially in its primary forms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.